Demographic characteristics and laboratory parameters of patients receiving rituximab prophylaxis for all 76 patients in total and 4 dose subgroups
| Characteristic . | Total (N = 76) . | Standard dose (375 mg/m2 × 4) (n = 24) . | Reduced dose (200 mg × 4) (n = 19) . | Intermediate dose (500 mg × 4) (n = 17) . | Other doses (n = 16) . |
|---|---|---|---|---|---|
| Female:male | 60:16 | 17:7 | 15:4 | 13:4 | 14:2 |
| Median age (range), y | 43.5 (18-78) | 41 (24-67) | 41 (18-74) | 46 (29-78) | 47 (19-65) |
| Median Hb (range), g/L | 133 (81*-171) | 135 (96-171) | 139 (81*-152) | 140 (123-163) | 125 (101-149) |
| Median platelets (range), × 109/L | 268 (83†-443) | 228 (109‡-333) | 287 (150-397) | 286 (199-443) | 306 (83†-390) |
| Median ADAMTS13 activity (range), % | 5 (<5-17) | <5 (<5-16) | 6 (<5-14) | 6 (<5-15) | 7 (<5-17) |
| Characteristic . | Total (N = 76) . | Standard dose (375 mg/m2 × 4) (n = 24) . | Reduced dose (200 mg × 4) (n = 19) . | Intermediate dose (500 mg × 4) (n = 17) . | Other doses (n = 16) . |
|---|---|---|---|---|---|
| Female:male | 60:16 | 17:7 | 15:4 | 13:4 | 14:2 |
| Median age (range), y | 43.5 (18-78) | 41 (24-67) | 41 (18-74) | 46 (29-78) | 47 (19-65) |
| Median Hb (range), g/L | 133 (81*-171) | 135 (96-171) | 139 (81*-152) | 140 (123-163) | 125 (101-149) |
| Median platelets (range), × 109/L | 268 (83†-443) | 228 (109‡-333) | 287 (150-397) | 286 (199-443) | 306 (83†-390) |
| Median ADAMTS13 activity (range), % | 5 (<5-17) | <5 (<5-16) | 6 (<5-14) | 6 (<5-15) | 7 (<5-17) |